Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 44 for “"castration-resistant prostate cancer"”.
-
Chemoligand therapy for metastatic castration-resistant prostate cancer
… disease of >70% of patients with metastatic castration-resistant prostate cancer (mCRPC) has moderate to high nonphysiological levels of a transmembrane protein known as prostate-specific membrane antigen (PSMA) and creates opportunities for precision medicine approaches. Using PSMA as a …
-
Characterizing glucocorticoid receptor in metastatic castration resistant prostate cancer
… and relevance in the context of enzalutamide resistant prostate cancer cells. Enzalutamide is a drug that functions to dampen androgen receptor (AR) signaling, thus inhibiting cancer dependency on the receptor protein. Although the application of the drug reduces AR signaling in these cancer …
-
The role of BET proteins in castration-resistant prostate cancer dissemination
The inevitable progression of advanced prostate cancer to castration resistance, and ultimately to lethal metastatic disease, depends on primary or acquired resistance to conventional androgen-deprivation therapy (ADT) and accumulated resistance mechanisms to evade androgen receptor (AR) …
-
Therapeutic Effects and Targeted Delivery of Eupenifeldin in Castration-Resistant Prostate Cancer
Castration-resistant prostate cancer (CRPC) poses a major therapeutic challenge, as it often fails to respond to standard treatments such as taxane-based chemotherapies, androgen receptor pathway inhibitors, and radioligand-based approaches1–4. Despite these treatments, CRPC remains incurable, and …
-
BOTH EFFECTOR AND INHIBITORY IMMUNE MECHANISMS ARE AMPLIFIED IN CASTRATION-RESISTANT PROSTATE CANCER
… is modulated by androgen ablation therapy for prostate cancer. Androgen ablation leads to apoptosis of primary prostate tumor and transient potentiation of immune function. However, immune inhibitory mechanisms employed by the tumor eventually prevent prolonged anti-tumor immunity. The …
-
Decoding the RNA cargo of plasma-derived extracellular vesicles in metastatic castration-resistant prostate cancer
… complement to tissue biopsies for monitoring cancer by capturing multiple molecular components circulating in body fluids, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), cell-free RNA (cfRNA) and extracellular vesicles (EVs). EVs are nanoscale structures surrounded by a lipid …
-
TMEFF2 is an epigenetic modulator that promotes androgen independent growth in castration-resistant prostate cancer cells
… the disease remains the second leading cause of cancer related deaths in men. Most patients initially respond to androgen deprivation treatment; however, a significant percentage of patients relapse with currently untreatable castration resistant prostate cancer (CRPC), during which the PCa cells …
-
Role of the extracellular matrix-integrin interaction in enzalutamide resistance of bone metastatic castration-resistant prostate cancer
Bone metastatic castration-resistant prostate cancer (bone mCRPC) is the most prevalent type of prostate cancer metastasis, accounting for 90% of all metastasis incidence. Its resistance to androgen-deprivation therapy (ADT). Enzalutamide (Enz) is a second-generation androgen-receptor (AR) …
-
The role of SRC family kinases in the development and progression of prostate cancer
Prostate cancer is the most common cancer in men and the second leading cause of cancer-related death in western world. Typically, the treatment of advanced and metastatic prostate cancer consists of castration therapy, which suppresses the development of the disease for 2 years in average. …
-
Study of the Gain-of-Function Mutant p53 and PARP1 in Triple-Negative Breast Cancer
<p>Cancer cells often lose expression of the p53 protein or express mutant forms of p53. Some of these mutant p53 proteins, called gain-of-function mutant p53, have gained oncogenic functions. Previously, our group observed mutant p53 R273H interacts with replicating DNA and upregulates the …
-
The DNA methylation landscape of metastatic prostate cancer: from characterization to liquid biopsy applications
… alterations are observed in virtually all cancer types, yet there is limited understanding of their role in tumorigenesis and evolution. The role of DNA methylation has been particularly elusive in this context. While this epigenetic mark has been extensively profiled in healthy and …
-
Augmenting Natural Killer cell antibody binding to enhance ovarian and prostate tumor cell killing via ADCC
Ovarian cancer and metastatic castration resistant prostate cancer (mCRPC) are a leading cause of cancer-related deaths worldwide. Natural killer (NK) cells are cytotoxic lymphocytes that rapidly kill tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is exclusively mediated …
-
Germline HOXB13 G84E Mutation Inhibits MEIS1-HOXB13 Driven Tumor Suppression in Prostate Cancer
Prostate cancer (PrCa) continues to pose a burden to adult men in the United States, having the highest incidence and second highest mortality rates. A prostate cancer diagnosis in an immediate family member increases risk 2-3 fold. Standard of care treatment of PrCa targets the Androgen Receptor …
-
Tmprss2-Erg Regulation Of Androgen Biosynthetic Enzyme Expression, Dht Synthesis, And Androgen Receptor Activation In Prostate Cancer
<p>Intratumoral androgen synthesis in prostate cancer (PCa) contributes to the development of castration-resistant prostate cancer (CRPC). Several enzymes responsible for androgen biosynthesis have been shown to be overexpressed in CRPC, thus, contributing to CRPC in a castrated environment. …
-
Androgen Receptor and Prostate Cancer Cell Heterogeneity
… receptor (AR) plays an important role in prostate cancer (PCa) development and has been the main therapeutic target in advanced PCa. AR expression is heterogeneous in both primary PCa and castration resistant prostate cancer (CRPC). However, the functional significance of AR heterogeneity …
-
The development of a novel therapeutic strategy for the treatment of prostate cancer by targeting metabolic signalling
Prostate cancer is one of the most prevalent cancers worldwide. The early stages of prostate cancer (PCa) are highly dependent on the androgen receptor (AR) pathway and hence therapies target this signalling axis. This approach is successful initially but invariably fails and the tumours progress …
-
Grk3 Connects Angiogenesis and Neuroendocrine Differentiation In Prostate Cancer By Activating Hdac2 That Epigenetically Represses Tsp1 and Rest
<p>Prostate cancer (PCa) is the second most frequent cancer and the second leading cause of mortality in men in the United States. Neuroendocrine prostate cancer (NEPC) is the aggressive subset of castration-resistant prostate cancer (CRPC), found in ~20% lethal CRPC. The mechanisms underlying the …
-
Quantitative analyses to study tumor clones dynamics and tumor heterogeneity
Prostate cancer is a highly heterogeneous disease and its manifestations can vary from indolent localized tumor to widespread metastases. This heterogeneity is also observed at the molecular level both inter- and intra-patient. Intra-patient heterogeneity in the clinical setting of men with …
-
CRISPR/Cas9 screenings and in silico investigations nominate low-frequency alterations in DNA repair genes as biomarkers for castration-resistant prostate cancers.
… the treatment of multiple tumor types, including prostate cancer (PCa), and are associated with therapeutic response in metastatic castration-resistant prostate cancer (mCRPC) patients characterized by defects in homologous recombination repair genes. Clinical trials results suggest that further …
-
Intratumoral Sting Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
… rare and are not observed in all tumor types. Castration resistant prostate cancer (CRPC) and pancreatic adenocarcinoma (PDAC) are two common lethal cancers that remain refractory to checkpoint blockade, requiring development of new therapeutic approaches to promote responsivity in patients …
Page 1 of 3